Analysis reveals allele frequency shifts in organoids treated with capivasertib and trametinib, suggesting pathways for cancer drug resistance.
Allele frequency distribution in parental vs capivasertib->trametinib treated organoids
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: